What question did this study set out to answer?

To evaluate the long-term efficacy of stapokibart treatment over 52 weeks in adult patients with moderate-to-severe atopic dermatitis.

March 28, 2025Dermatitis

Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic Dermatitis

View Full Paper

Ask AI

Bookmark

Authors

YZYan ZhaoQingdao University LZLitao ZhangTianjin University of Traditional Chinese Medicine LWLiming WuTianjin University of Science and Technology

Discussion

Member takes

Implication

Randomized trial demonstrates sustained disease control with long-term stapokibart in moderate-to-severe atopic dermatitis, indicating durable benefit even in late responders.

Key Points

To evaluate the long-term efficacy of stapokibart treatment over 52 weeks in adult patients with moderate-to-severe atopic dermatitis.
Post hoc analysis of 237 adult patients from a phase 3 clinical trial (NCT05265923).
Patients received stapokibart 300 mg (loading dose 600 mg) every 2 weeks during a 16-week double-blind period and continued the same regimen through a 36-week maintenance period.
Among patients meeting coprimary endpoints at week 16, 100% maintained EASI-75 and 92.2% maintained IGA 0/1 at week 20; at week 52, retention reached 99.0% and 87.0%, respectively.
Among week 16 non-responders, 65.4% achieved EASI-75 and 18.1% achieved IGA 0/1 at week 20, rising to 86.8% and 50.0% at week 52, respectively.
Patient-reported outcomes showed sustained improvements throughout the 52-week treatment duration.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/6a799fffe357fbdac5892280 https://doi.org/10.1089/derm.2024.0533

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates sustained disease control with long-term stapokibart in moderate-to-severe atopic dermatitis, indicating durable benefit even in late responders.

Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic Dermatitis

Discussion

Member takes

Implication

Key Points

Cite This Study

Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic Dermatitis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider